Previous close | 0.0870 |
Open | 0.0870 |
Bid | 0.0890 x 50000000 |
Ask | 0.0900 x 34112000 |
Day's range | 0.0860 - 0.0900 |
52-week range | 0.0730 - 0.3500 |
Volume | |
Avg. volume | 680,098 |
Market cap | 60.191M |
Beta (5Y monthly) | 1.11 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0150 |
Earnings date | 23 Aug 2022 - 29 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 0.42 |
Figure 1 Quad RNA ddPCR (Pooled) Figure 2 Quad RNA ddPCR (Female) LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)Animal study conducted at MCRI in collaboration with Jain Foundation in the USStudy results showed significant decreases in target CD49d RNA and key immune cell RNA levels in the muscleData supports progression into a longer-term efficacy study planned for 3Q/4Q2022 Mark Diamond, Antisense Therapeutics Mana
New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week. Dr. George Tachas, the Company’s Director of Drug Discovery and Patents, will present an e-poster on new data from its Phase II study of ATL1102 in patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic disorder th
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...